tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ACLX Stock Latest News

Arcellx Inc.: Promising Developments and Strategic Positioning Drive Buy Rating
RatingsArcellx Inc.: Promising Developments and Strategic Positioning Drive Buy Rating
3d ago
ACLX
Arcellx, Inc. Reports Increased Loss Amid Rising Expenses
PremiumCompany Announcements
Arcellx, Inc. Reports Increased Loss Amid Rising Expenses
4d ago
ACLX
Arcellx’s Promising Clinical Data and Strong Financial Position Justify Buy Rating with $105 Target Price
PremiumRatings
Arcellx’s Promising Clinical Data and Strong Financial Position Justify Buy Rating with $105 Target Price
10d ago
ACLX
Promising Developments and Strategic Plans Boost Confidence in Arcellx Inc.’s Anito-cel
PremiumRatings
Promising Developments and Strategic Plans Boost Confidence in Arcellx Inc.’s Anito-cel
11d ago
ACLX
Arcellx Inc’s Promising Developments and Strategic Partnerships Drive Buy Rating
PremiumRatings
Arcellx Inc’s Promising Developments and Strategic Partnerships Drive Buy Rating
11d ago
ACLX
Arcellx’s Anito-cel Shows Promising Phase II Results and Market Potential, Earning Buy Rating
PremiumRatingsArcellx’s Anito-cel Shows Promising Phase II Results and Market Potential, Earning Buy Rating
13d ago
ACLX
Arcellx participates in a conference call with Truist
Premium
The Fly
Arcellx participates in a conference call with Truist
13d ago
ACLX
Arcellx price target raised to $130 from $121 at Canaccord
Premium
The Fly
Arcellx price target raised to $130 from $121 at Canaccord
14d ago
ACLX
Arcellx management to meet with Piper Sandler
PremiumThe Fly
Arcellx management to meet with Piper Sandler
20d ago
ACLX
Arcellx’s iMMagine-3 Study: A Potential Game-Changer for Multiple Myeloma Treatment
PremiumCompany Announcements
Arcellx’s iMMagine-3 Study: A Potential Game-Changer for Multiple Myeloma Treatment
20d ago
ACLX
Arcellx Advances in Autoimmune Treatment with Anitocabtagene Autoleucel Study
PremiumCompany Announcements
Arcellx Advances in Autoimmune Treatment with Anitocabtagene Autoleucel Study
20d ago
ACLX
Arcellx resumed with a Buy at Stifel
PremiumThe Fly
Arcellx resumed with a Buy at Stifel
1M ago
ACLX
Arcellx assumed with a Neutral at Cantor Fitzgerald
PremiumThe FlyArcellx assumed with a Neutral at Cantor Fitzgerald
1M ago
ACLX
Promising Outlook for Arcellx Inc.: Buy Rating Backed by Strong Efficacy, Safety, and Financial Position
Premium
Ratings
Promising Outlook for Arcellx Inc.: Buy Rating Backed by Strong Efficacy, Safety, and Financial Position
1M ago
ACLX
Arcellx Inc’s Strong Positioning and Financial Stability Support Buy Rating Amid Anticipated FDA Approval
Premium
Ratings
Arcellx Inc’s Strong Positioning and Financial Stability Support Buy Rating Amid Anticipated FDA Approval
2M ago
ACLX
3 Stocks to Buy Now, According to the Technical Analysis
PremiumMarket News
3 Stocks to Buy Now, According to the Technical Analysis
3M ago
CXW
ACLX
Promising Clinical Outcomes and Low Toxicity Profile Position Anito-cel as a Leading Therapy for Relapsed/Refractory Multiple Myeloma
PremiumRatings
Promising Clinical Outcomes and Low Toxicity Profile Position Anito-cel as a Leading Therapy for Relapsed/Refractory Multiple Myeloma
3M ago
ACLX
Arcellx, Inc. Reports Increased Losses Amid Rising R&D Costs
PremiumCompany Announcements
Arcellx, Inc. Reports Increased Losses Amid Rising R&D Costs
3M ago
ACLX
Promising Prospects for Arcellx Inc: Strong Efficacy and Strategic Partnerships Drive Buy Rating
PremiumRatings
Promising Prospects for Arcellx Inc: Strong Efficacy and Strategic Partnerships Drive Buy Rating
3M ago
ACLX
Promising Outlook for Arcellx Inc.: Buy Rating Backed by Strong Anito-cel Therapy Performance and Favorable Safety Profile
PremiumRatingsPromising Outlook for Arcellx Inc.: Buy Rating Backed by Strong Anito-cel Therapy Performance and Favorable Safety Profile
3M ago
ACLX
Arcellx Inc: Promising Developments and Strong Clinical Data Drive Buy Rating
Premium
Ratings
Arcellx Inc: Promising Developments and Strong Clinical Data Drive Buy Rating
3M ago
ACLX
Arcellx reports Q2 EPS (94c), consensus ($1.03)
Premium
The Fly
Arcellx reports Q2 EPS (94c), consensus ($1.03)
3M ago
ACLX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >